Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression
Using patient-reported PHQ-9 scoring to evaluate ESCAPE-TRD results, esketamine NS produced superior short- and long-term efficacy vs. quetiapine XR among individuals with TRD treated according to US label.
Authors
- Pushpike Thilakarathne
- Yordan Godinov
- Annie Qu (ORCID: https://orcid.org/0000-0002-8396-7828)
- Urvi Desai (ORCID: https://orcid.org/0000-0001-5196-7201)
- Jason Doran (ORCID: https://orcid.org/0000-0002-5501-9433)
- Noam Y. Kirson (ORCID: https://orcid.org/0000-0001-5200-6883)
- Kristin K. Clemens (ORCID: https://orcid.org/0000-0001-9636-5597)
- Kruti Joshi (ORCID: https://orcid.org/0000-0001-9263-5158)
- Dalia Eid
- Benoît Rive
Institutions
- Johnson & Johnson (United States) (US)
- Johnson & Johnson (France) (FR)
- Health Solutions (Sweden) (SE)
- Johnson & Johnson (Israel) (IL)
- Research Institute for Genetic and Human Therapy (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-08-03
- DOI
- https://doi.org/10.1080/03007995.2025.2555483
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00